Immunovia AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was SEK 0.358 million compared to SEK 0.377 million a year ago. Revenue was SEK 0.381 million compared to SEK 0.386 million a year ago. Net loss was SEK 22.93 million compared to SEK 36.13 million a year ago. Basic loss per share from continuing operations was SEK 1.01 compared to SEK 1.6 a year ago. Diluted loss per share from continuing operations was SEK 1.01 compared to SEK 1.6 a year ago.
For the nine months, sales was SEK 0.643 million compared to SEK 0.539 million a year ago. Revenue was SEK 0.691 million compared to SEK 0.612 million a year ago. Net loss was SEK 100.77 million compared to SEK 108.84 million a year ago. Basic loss per share from continuing operations was SEK 4.45 compared to SEK 4.81 a year ago. Diluted loss per share from continuing operations was SEK 4.45 compared to SEK 4.81 a year ago.